- Home
- STKS vs SGMT Comparison
STKS vs SGMT Comparison
Compare STKS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- SGMT
- Stock Information
- Founded
- STKS 2004
- SGMT 2006
- Country
- STKS United States
- SGMT United States
- Employees
- STKS N/A
- SGMT N/A
- Industry
- STKS Restaurants
- SGMT
- Sector
- STKS Consumer Discretionary
- SGMT
- Exchange
- STKS Nasdaq
- SGMT Nasdaq
- Market Cap
- STKS 158.5M
- SGMT 269.2M
- IPO Year
- STKS N/A
- SGMT 2023
- Fundamental
- Price
- STKS $4.15
- SGMT $9.40
- Analyst Decision
- STKS Hold
- SGMT Strong Buy
- Analyst Count
- STKS 3
- SGMT 5
- Target Price
- STKS $4.83
- SGMT $26.60
- AVG Volume (30 Days)
- STKS 334.4K
- SGMT 1.4M
- Earning Date
- STKS 08-05-2025
- SGMT 08-13-2025
- Dividend Yield
- STKS N/A
- SGMT N/A
- EPS Growth
- STKS N/A
- SGMT N/A
- EPS
- STKS N/A
- SGMT N/A
- Revenue
- STKS $799,478,000.00
- SGMT N/A
- Revenue This Year
- STKS $26.92
- SGMT N/A
- Revenue Next Year
- STKS $5.39
- SGMT N/A
- P/E Ratio
- STKS N/A
- SGMT N/A
- Revenue Growth
- STKS 138.50
- SGMT N/A
- 52 Week Low
- STKS $2.37
- SGMT $1.73
- 52 Week High
- STKS $5.42
- SGMT $10.43
- Technical
- Relative Strength Index (RSI)
- STKS 46.53
- SGMT 61.34
- Support Level
- STKS $3.80
- SGMT $8.49
- Resistance Level
- STKS $5.26
- SGMT $9.98
- Average True Range (ATR)
- STKS 0.50
- SGMT 0.76
- MACD
- STKS -0.06
- SGMT -0.07
- Stochastic Oscillator
- STKS 24.10
- SGMT 65.00
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.